FDA Inspection
Samson Pharmaceuticals, IncSamson Pharmaceuticals, Inc – FDA Inspection, Apr 29, 2026
Record Details
This FDA Inspection record concerns Samson Pharmaceuticals, Inc, with an inspection on April 29, 2026, issued by the Los Angeles District Office, covering human drugs.
View Company Profile
ID · c5ccd952-6c74-486d-a807-a72f44173f28
Inspection Facts
- Inspection number
- 1314718
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
8- 21 CFR 211.113(b)Procedures for sterile drug products
- 21 CFR 211.160(a)Lab controls established, including changes
- 21 CFR 211.160(b)(4)Calibration - at intervals, written program, remedial action
- 21 CFR 211.166(a)Lack of written stability program
- 21 CFR 211.192No written record of investigation
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.42(c)(10)(iv)Environmental Monitoring System
- 21 CFR 211.84(d)(2)Establish reliability of supplier's C of A
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Samson Pharmaceuticals, Inc
2| Date | Classification | Office | Project area |
|---|---|---|---|
| February 9, 2018 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| March 25, 2016 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Samson Pharmaceuticals, Inc
- FDA Inspection 1040504 - 2018-02-09
- FDA Inspection 988639 - 2016-03-25
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.